New drug combo targets tough adrenal cancer
NCT ID NCT05036434
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests two drugs, pembrolizumab and lenvatinib, in 30 adults with advanced adrenal cortical carcinoma that has worsened after standard chemotherapy. The goal is to see if the combination can shrink or slow the cancer. Participants receive the drugs intravenously and by mouth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) and lenvatinib (Lenvima)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced adrenal cancer that has stopped responding to standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial with only 30 participants and no comparison group. The combination may not work or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver tumors targeted directly: old pump, new drug
- Study aims to uncover hidden side effects of common adrenal cancer drug
- New registry aims to unlock secrets of rare adrenal cancer
- Scientists search for keys to unlock immune attack on rare adrenal cancer
- Scientists investigate adrenal tumors and seek better therapies
- New hope for rare cancers? drug combo shows promise in early trial